UK Biobank Observational Data Link Five-Plus Daily Coffee Cups to Lower Cirrhosis and Liver Cancer Incidence

The study tracked incident cirrhosis, hepatocellular carcinoma, and liver deaths over follow-up using hospital records and death registries. Coffee intake was self-reported at baseline; researchers also examined MRI liver fat and proteomic markers. Dose-response gradients appeared for both caffeinated and decaffeinated coffee, with smaller risk reductions when sugar or sweeteners were added. Absolute incidence rates remained low even in the reference group, limiting clinical translation.

Prior cohort studies in NEJM and Gastroenterology have reported similar inverse associations with fibrosis progression and HCC, often attributing effects to chlorogenic acids and reduced inflammation. The current work strengthens the pattern by aligning clinical endpoints with imaging and biomarker data, yet residual confounding by diet quality, alcohol avoidance, and socioeconomic status cannot be excluded. No randomization occurred, so causality is unproven.

Regulatory bodies have not altered liver-disease prevention guidance on the basis of these findings. Future work requires Mendelian randomization or long-term RCTs that measure hard outcomes while controlling for total polyphenol intake and lifestyle clusters.

Next steps include identifying specific bioactive compounds and testing whether targeted coffee interventions alter liver-fat trajectories in at-risk populations.